Eculizumab

Brand names: Epysqli · Active ingredient: Eculizumab

In short: EPYSQLI is indicated for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis. EPYSQLI is indicated for the treatment of patients with atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy.

Forms & strengthsInjection: 300 mg/30 mL (10 mg/mL) as a clear to slightly opalescent and colorless solution in a single-dose vial.
LabelTeva Pharmaceuticals USA, Inc.
Label updatedJul 14, 2026

What is Eculizumab used for?

EPYSQLI is indicated for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis.

EPYSQLI is indicated for the treatment of patients with atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy.

Limitation of Use

EPYSQLI is not indicated for the treatment of patients with Shiga toxin E. coli related hemolytic uremic syndrome (STEC-HUS).

EPYSQLI is indicated for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive.

EPYSQLI is indicated for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive.

âš  Boxed warning (FDA's strongest warning)

Eculizumab products, complement inhibitors, increase the risk of serious infections caused by

Neisseria meningitidis

. Life-threatening and fatal meningococcal infections have occurred in patients treated with complement inhibitors. These infections may become rapidly life-threatening or fatal if not recognized and treated early.

Complete or update vaccination for meningococcal bacteria (for serogroups A, C, W, Y, and B) at least 2 weeks prior to the first dose of EPYSQLI, unless the risks of delaying therapy with EPYSQLI outweigh the risk of developing a serious infection. Comply with the most current Advisory Committee on Immunization Practices (ACIP) recommendations for vaccinations against meningococcal bacteria in patients receiving a complement inhibitor. See

Warnings and Precautions

(5.1) for additional guidance on the management of the risk of serious infections caused by meningococcal bacteria.

Patients receiving eculizumab products are at increased risk for invasive disease caused by

Neisseria meningitidis

, even if they develop antibodies following vaccination. Monitor patients for early signs and symptoms of serious meningococcal infections and evaluate immediately if infection is suspected.

Because of the risk of serious meningococcal infections, EPYSQLI is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called EPYSQLI REMS .

Eculizumab dosage

Vaccinate patients against meningococcal infection (serogroups A, C, W, Y, and B) according to current ACIP recommendations at least 2 weeks prior to initiation of EPYSQLI .

If urgent EPYSQLI therapy is indicated in a patient who is not up to date with meningococcal vaccines according to ACIP recommendations, provide the patient with antibacterial drug prophylaxis and administer these vaccines as soon as possible.

Healthcare providers who prescribe EPYSQLI must enroll in the EPYSQLI REMS .

The recommended dosage of EPYSQLI for the treatment of PNH in patients 18 years of age and older is administered as an intravenous infusion as follows:

600 mg weekly for the first 4 weeks, followed by

900 mg for the fifth dose 1 week later, then

900 mg every 2 weeks thereafter.

Administer EPYSQLI at the recommended dosage regimen time points, or within two days of these time points .

The recommended dosage of EPYSQLI for the treatment of aHUS, gMG, or NMOSD in patients 18 years of age and older is administered as an intravenous infusion as follows:

900 mg weekly for the first 4 weeks, followed by

1,200 mg for the fifth dose 1 week later, then

1,200 mg every 2 weeks thereafter.

The recommended dosage of EPYSQLI for the treatment of aHUS in pediatric patients less than 18 years of age is administered as an intravenous infusion based upon body weight, according to the following schedule (Table 1):

Patient Body Weight | Induction | Maintenance

40 kg and over | 900 mg weekly for the first 4 weeks | 1,200 mg at week 5; then 1,200 mg every 2 weeks

30 kg to less than 40 kg | 600 mg weekly for the first 2 weeks | 900 mg at week 3; then 900 mg every 2 weeks

20 kg to less than 30 kg | 600 mg weekly for the first 2 weeks | 600 mg at week 3; then 600 mg every 2 weeks

10 kg to less than 20 kg | 600 mg single dose at Week 1 | 300 mg at week 2; then 300 mg every 2 weeks

5 kg to less than 10 kg | 300 mg single dose at Week 1 | 300 mg at week 2; then 300 mg every 3 weeks

Administer EPYSQLI at the recommended dosage regimen time points, or within two days of these time points.

For adult and pediatric patients with aHUS, and adult patients with gMG or NMOSD, supplemental dosing of EPYSQLI is required in the setting of concomitant plasmapheresis or plasma exchange, or fresh frozen plasma infusion (PE/PI) (Table 2). …

How to take Eculizumab — instructions & advice from the label

Advise the patients and/or caregivers to read the FDA-approved patient labeling (Medication Guide).

Serious Meningococcal Infections

Advise patients of the risk of serious meningococcal infection. Inform patients of the need to complete or update their meningococcal vaccinations at least 2 weeks prior to receiving the first dose of EPYSQLI or receive antibacterial drug prophylaxis if EPYSQLI treatment must be initiated immediately and they have not been previously vaccinated. Inform patients of the requirement to be revaccinated according to current ACIP recommendations for meningococcal infection while on EPYSQLI therapy .

Inform patients that vaccination may not prevent serious meningococcal infection and to seek immediate medical attention if the following signs or symptoms occur :

fever

fever and a rash

fever with high heart rate

headache with nausea or vomiting

headache and a fever

headache with a stiff neck or stiff back

confusion

muscle aches with flu-like symptoms

eyes sensitive to light

Inform patients that they will be given a Patient Safety Card for EPYSQLI that they should carry with them at all times during and for 3 months following treatment with EPYSQLI. …

Warnings & precautions

Do not take this medicine if: EPYSQLI is contraindicated for initiation in patients with unresolved serious Neisseria meningitidis infection .

Eculizumab products, complement inhibitors, increase a patient's susceptibility to serious, life-threatening, or fatal infections caused by meningococcal bacteria (septicemia and/or meningitis) in any serogroup, including non-groupable strains. Life-threatening and fatal meningococcal infections have occurred in both vaccinated and unvaccinated patients treated with complement inhibitors. The initiation of EPYSQLI treatment is contraindicated in patients with unresolved serious Neisseria meningitidis infection.

Complete or update meningococcal vaccination (for serogroups A, C, W, Y, and B) at least 2 weeks prior to administration of the first dose of EPYSQLI, according to current ACIP recommendations for patients receiving a complement inhibitor. Revaccinate patients in accordance with ACIP recommendations, considering the duration of therapy with EPYSQLI. Note that ACIP recommends an administration schedule in patients receiving complement inhibitors that differs from the administration schedule in the vaccine prescribing information. If urgent EPYSQLI therapy is indicated in a patient who is not up to date with meningococcal vaccines according to ACIP recommendations, provide the patient with antibacterial drug prophylaxis and administer meningococcal vaccines as soon as possible. Various durations and regimens of antibacterial drug prophylaxis have been considered, but the optimal durations and drug regimens for prophylaxis and their efficacy have not been studied in unvaccinated or vaccinated patients receiving complement inhibitors, including eculizumab products. …

Eculizumab side effects

The following serious adverse reactions are discussed in greater detail in other sections of the labeling:

Serious Meningococcal Infections

Other Infections

Monitoring Disease Manifestations after EPYSQLI Discontinuation

Thrombosis Prevention and Management

Infusion-Related Reactions

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Meningococcal infections are the most important adverse reactions experienced by patients receiving eculizumab. In PNH clinical studies, two patients experienced meningococcal sepsis. Both patients had previously received a meningococcal vaccine. In clinical studies among patients without PNH, meningococcal meningitis occurred in one unvaccinated patient. Meningococcal sepsis occurred in one previously vaccinated patient enrolled in the retrospective aHUS study during the post-study follow-up period .

PNH

The data described below reflect exposure to eculizumab in 196 adult patients with PNH, age 18-85, of whom 55% were female. All had signs or symptoms of intravascular hemolysis. Eculizumab was studied in a placebo-controlled clinical study (PNH Study 1, in which 43 patients received eculizumab and 44, placebo); a single arm clinical study (PNH Study 2); and a long term extension study (E05-001). …

Drug interactions

Concomitant use of eculizumab products with plasma exchange (PE), plasmapheresis (PP), fresh frozen plasma infusion (PE/PI), or in patients with gMG on concomitant IVIg treatment can reduce serum eculizumab product concentrations and requires a supplemental dose of EPYSQLI .

Concomitant use of eculizumab products with neonatal Fc receptor (FcRn) blockers may lower systemic exposures and reduce effectiveness of eculizumab products. Closely monitor for reduced effectiveness of EPYSQLI.

About this medicine

Eculizumab-aagh, a complement inhibitor, is a recombinant humanized monoclonal IgG2/4κ antibody produced in a Chinese Hamster Ovary cell line expression system and purified by standard bioprocess technology .

Eculizumab-aagh contains human constant regions from human IgG2 sequences and human IgG4 sequences and murine complementarity-determining regions grafted onto the human framework light- and heavy-chain variable regions. Eculizumab-aagh is composed of two 448 amino acid heavy chains and two 214 amino acid light chains and has a molecular weight of approximately 148 kDa.

EPYSQLI (eculizumab-aagh) injection is a sterile, preservative-free, clear to slightly opalescent and colorless solution for intravenous infusion and is supplied in a 30 mL single-dose vial. Each mL contains 10 mg of eculizumab-aagh, dibasic sodium phosphate (0.77 mg), monobasic sodium phosphate (0.55 mg), polysorbate 80 (0.22 mg) (vegetable origin), trehalose (86 mg), and Water for Injection, USP. The pH is 7. …

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 1fa1aa80-1c59-44d4-9841-b6c52882651b. Read the full official label on DailyMed.